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Glossary of Abbreviations 28 
AVR- Aortic valve replacement 29 
MVR-Mitral valve replacement 30 
TAVR-Transcatheter Aortic Valve Replacement 31 
NYHA-New York Heart Association 32 
ESRD- End stage renal disease 33 
LOS- Length of stay 34 
DM- Diabetes mellitus 35 
HR- Hazard Ratio 36 
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Central Picture 72 
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92 
Central Message 93 
94 
The majority of dialysis-dependent patients undergoing valve replacement have poor survival. 95 
Given that survival is short, biological valves may be the more appropriate choice in most 96 
patients. 97 
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 133 
Perspective Statement 134 
 135 
There is little data to guide valve type selection in dialysis-dependent patients.  Our findings 136 
show that long-term survival is poor in patients undergoing valve replacement surgery. Due to 137 
the short survival time, a biological valve is likely sufficient for most patients; however, young 138 
patients without diabetes or heart failure may survive long enough to justify placement of a 139 
mechanical valve.  140 
 141 
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Structured Abstract 172 
 173 
Objective: Valve selection in dialysis-dependent patients can be difficult because long-term 174 
survival is diminished and bleeding risks while on anticoagulation are greater in patients with 175 
renal failure.  This study analyzed long-term outcomes of dialysis-dependent patients undergoing 176 
valve replacement to help guide optimal prosthetic valve type selection  177 
 Methods: Dialysis-dependent patients undergoing aortic and/or mitral valve replacement at 3 178 
institutions over 20 years were examined. The primary outcome was long term survival.  A Cox 179 
regression model was used to estimate survival by five ages, presence of diabetes, and/or heart 180 
failure symptoms.  181 
Results: 423 available patients were analyzed.  341 patients had biological and 82 had 182 
mechanical valves. Overall complication and 30-day mortality rates were similar between the 183 
groups. Thirty day readmission rates for biological and mechanical groups were 15% (50/341) 184 
and 28% (23/82, p=0.005). Five year survival was 23% and 33% for the biological and 185 
mechanical groups, respectively. After adjusting for age, NYHA class, and diabetes using a 186 
multivariable Cox regression model, survival was similar between groups (HR 0.93, CI 0.66-187 
1.29, p=0.8). A Cox regression model based on age, diabetes, and heart failure, estimated that 188 
patients only 30 or 40 years old, with NYHA class I-II failure without diabetes had a >50% 189 
estimated 5-year survival(p=<0.001).   190 
Conclusion: Patients who were on dialysis and underwent valve replacement surgery had poor 191 
long-term survival.  Young patients without diabetes or NYHA III or IV symptoms may survive 192 
long enough to justify placement of a mechanical valve; however, a biological valve is suitable 193 
for most patients.  194 
Abstract: 249/250 words 195 
 196 
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Introduction 197 
 198 
There are 120,000 cases of new end stage renal disease (ESRD) diagnosed every year and 199 
this number continues to rise.  Approximately 90% of these patients are started on hemodialysis.  200 
Mortality rates among dialysis patients remain high.  Overall 5 year survival for patients with 201 
ESRD on dialysis is about 40% (1).  Cardiovascular diseases comprise the leading cause of death 202 
in this patient population, as a result cardiac surgeons perform an increasing number of high risk 203 
operations, including valve replacement surgery (1).  204 
There is debate about the optimal choice of prosthesis for valve replacement in dialysis-205 
dependent patients.  Early AHA/ACC guidelines (1998) recommended placement of mechanical 206 
valves in all dialysis-dependent patients undergoing valve replacement surgery (2). However, 207 
based on small reports that showed equivalent outcomes in patients who received both types of 208 
valves, in 2006, the guidelines were revised and ceased to have explicit criteria for valve 209 
selection; the most current guidelines also do not give specific guidance. The most current 210 
recommendation is that valve selection should be individualized to the patient (3). Unfortunately, 211 
there is a paucity of reports which aid in this selection process, as most studies have small 212 
samples sizes, are single center, and/or are retrospective in nature.   213 
Compared to mechanical valves, biological valves have poor longevity which has been 214 
attributed to advanced calcification and degeneration (4). These processes are thought to be 215 
exacerbated by hematological changes in patients with ESRD; however studies comparing 216 
mechanical vs biological valves in hemodialysis dependent patients have not shown a definitive 217 
survival advantage of one valve type (5-7).  A prevailing challenge with mechanical valve 218 
replacement in the dialysis population is that these patients require frequent AV fistulae access 219 
and are more prone to major bleeding events(8).   Given the poor long-term survival of dialysis-220 
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dependent patients it is reasonable to believe that those receiving bioprosthetic valves may die 221 
before valve failure.  222 
The purpose of this study was to compare postoperative outcomes and long-term survival 223 
of patients who required pre-operative hemodialysis and underwent valve replacement surgery 224 
with either biological or mechanical valves.  We hypothesized that the majority of patients would 225 
not live long enough postoperatively to justify placement of a mechanical valve. 226 
Methods 227 
All patients who were on pre-operative hemodialysis who underwent mitral valve 228 
replacement (MVR) or aortic valve replacement (AVR) between January 1998 and August 2017 229 
were identified retrospectively at 3 institutions located in the Midwest. Two institutions were 230 
major academic hospitals and one was a community hospital.  The requirement for individual 231 
consent for this study was waived by the institutional review boards at each institution.  Inclusion 232 
criteria included patients who underwent aortic and/or mitral valve replacement and required 233 
preoperative hemodialysis for≥30 days. Those who underwent transcatheter valve replacement 234 
(TAVR) or aortic root replacement were excluded.  EuroScore II was calculated based on age, 235 
gender, renal impairment, extracardiac arteriopathy, poor mobility, previous cardiac surgery, 236 
chronic lung disease, active endocarditis, critical preoperative state, diabetes on insulin, NYHA 237 
class, left ventricular function, recent MI, pulmonary hypertension, urgency of operation, weight 238 
of intervention, and surgery on thoracic aorta. If the data was not available the variable was 239 
omitted from the EuroScore II calculation.  Preoperative diabetes does not distinguish between 240 
those patients who were on insulin.    241 
The primary outcome measure was long-term survival. Secondary outcomes included 242 
estimated survival by a Cox-regression model for 5 ages (30, 40, 50, 60, and 70 years old) and 243 
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presence or absence of diabetes mellitus and/or heart failure, 30-day mortality, hospital length of 244 
stay (LOS), ventilator hours, need for reoperation, and 30-day readmission rates.  Survival data 245 
were obtained for all patients through interrogation of institutional medical records databases, 246 
obituaries, and the Social Security Death Index.  Operative mortality was defined as death that 247 
occurred during the index hospitalization or within 30 days of the operation.  Long-term survival 248 
data included death from all causes.  The follow-up closing date was October 7th, 2017.  249 
The Shapiro-Wilk test was used to assess the distribution of the study population. To 250 
address missing data, multiple imputation was employed. The expected maximization method 251 
was used for continuous variables and regression was used for categorical variables. Continuous 252 
data were reported as mean ± SD, or median [Interquartile range] as appropriate, and were 253 
compared between groups using the Students t-test and Mann-Whitney U test, respectively.  254 
Categorical variables were compared using chi-squared analysis.  Survival estimates were 255 
generated using the Kaplan-Meier method and subsequently compared using the log rank test.  256 
Predictors of mortality were identified by univariable analysis using a p-value cutoff of 0.1 and 257 
then entered into a multivariable analysis.  A multivariable Cox regression model was used to 258 
estimate survival based on those factors found to be significant for survival: age and the presence 259 
or absence of diabetes and/or NYHA III or IV symptoms.  Propensity score matching using a 260 
caliper of 0.1 was performed using variables from Table 1.A logistic model with nearest 261 
neighbor algorithm, greedy method, and a 1:1 match was used. Variables selected included age, 262 
diabetes, EuroScore II, redo operation, valvulopathy, coronary artery disease, gender, 263 
endocarditis, hypertension, peripheral vascular disease, cerebrovascular disease, previous valve 264 
procedure, preoperative ejection fraction, and preoperative NYHA III or IV heart failure 265 
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symptoms. Statistics were done using STATA Version 15.0 (STATA Corp, College Station, 266 
Texas). A P-value of ≤0.05 was considered statistically significant.  267 
Results 268 
 269 
Four hundred and ninety-two patients underwent valve replacement over the 20 year 270 
period and 423 were included in the analysis. Sixty-nine patients were excluded because they 271 
underwent aortic root replacement or TAVR. Three-hundred and forty-one patients underwent 272 
replacement with a biological valve and 82 underwent replacement with a mechanical valve.  273 
There were no patients who had undergone preoperative kidney transplantation. One-hundred 274 
and forty nine (35%) were from Indiana University, 196 (46%) were from Barnes-Jewish 275 
Hospital, and 80 (18%) were from Christian Northeast Hospital. Median follow up was 1.28 276 
[IQR: 0.2, 3.1] years and survival data were available for 81% of patients.  Baseline preoperative 277 
characteristics are summarized in Table 1.   The average age for patients who had biological 278 
valves was 60 ±13.5 and 51±12.8 years for patients who had mechanical valves placed 279 
(p=<0.001).  The average EuroScore II was 12.3%±7.8 and 8.9%±6.7 for the biological valve 280 
and mechanical valve groups, respectively (p=0.002).  Eighty-one (23%) and 14 (17%) of the 281 
biological and mechanical valve groups were reoperations, respectively.  More specifically, 54 282 
(15%) of the biological valve group had a previous valve operation and 11 (13%) of the 283 
mechanical valve group had a previous valve operation.   There were no significant differences 284 
between evaluated intra-operative variables (Table 1).  Overall complication and 30-day 285 
mortality rates were similar between groups (Table 2). However, 23/82 (28%) of patients in the 286 
mechanical valve group were readmitted within 30 days compared to 50/341 (15%) in the 287 
biological valve group (p=0.005).   Regarding 30 day mortality, cause of mortality was available 288 
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for 40/55 patients.  Of these patients, 20 died from a cardiac related cause, 5 were pulmonary 289 
related, 5 were neurologic, 1 was vascular, and 10 were sepsis related.  290 
Presence of diabetes mellitus, age, and NYHA III or IV symptoms were all significant 291 
predictors of mortality (Table 3). Having two or more valves replaced was not a predictor of 292 
poor outcomes (HR: 0.873, (95% CI: 0.625-1.220, p=0.43) as demonstrated by the univariable 293 
Cox analysis. Based on Kaplan Meier analysis, five year survival was 23% for the biological 294 
valve group and 33% for the mechanical valve group. Ten-year survival was 5% and 20% with a 295 
median survival of 2.06 [1.56, 2.36] and 3.02 [1.69, 4.34] years for the biological and 296 
mechanical groups, respectively (p=0.017, Figure 1). No patients in either group survived longer 297 
than 13 years.  When adjusted for age, NYHA class, and diabetes using a multivariable Cox 298 
regression model, survival was similar between groups (HR 0.93, 95% CI 0.66-1.29, p=0.86, 299 
Figure 2).  Propensity score matching yielded 75 patients in the biological valve group and 75 300 
patients in the mechanical valve group (Supplemental Figures 1-4).  Survival was similar in each 301 
group (Supplemental Figure 4). Patients who received a biological valve spent significantly more 302 
hours on the ventilator (Supplemental Table 1).   303 
A Kaplan Meier analysis comparing patients with and without endocarditis showed a 5 304 
year survival of 25% and 25%, respectively (p=0.591). Cox regression using variables found to 305 
be significant for long-term survival was employed to estimate 5-year survival based on five ages 306 
(30, 40, 50, 60, and 70 years old), diabetes, and NYHA class ≥3 (p=<0.001, Figure 4, Table 4).  307 
Only patients who were 30 or 40 years old and in NYHA class I-II failure without diabetes had a 308 
>50% estimated 5-year survival (Harrell’s C coefficient 0.61, Table 4).  309 
 310 
 311 
 312 
 313 
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Discussion 314 
 315 
The vast majority of hemodialysis patients who underwent valve replacement surgery had 316 
poor long-term survival. At five years postoperatively, only 23% and 33% of patients were alive 317 
in the biological and mechanical groups, respectively.  These findings are similar to previous 318 
smaller studies.  Brinkman et al. showed that overall survival of patients undergoing dialysis at 6 319 
years was 15.9% in a cohort of 72 patients (9), and Zhibing and colleagues showed an estimated 320 
5 year patient survival rate with bioprosthetic valves of 53% versus 56.8% with mechanical 321 
valves in 73 dialysis-dependent patients who had undergone surgery (4).   322 
Cardiovascular disease remains the most common cause of death in patients requiring 323 
dialysis. This patient population represents an ongoing challenge to physicians as they are high 324 
risk surgical candidates (1). Valve selection in dialysis patients presents a dilemma to cardiac 325 
surgeons as they must assess the risk for accelerated bioprosthetic valve deterioration due to 326 
calcification against the morbidity and mortality associated with anticoagulation (4,10,11).  327 
Anticoagulation in this patient population can be problematic, especially in those who require 328 
vascular access several times per week.  Furthermore, they must assess these risks and benefits in 329 
the face of known poor long-term survival.  Previous guidelines established in 1998 from the 330 
American College of Cardiology and American Heart Association recommended placement of 331 
mechanical heart valve prostheses for patients with ESRD requiring dialysis (2).  These 332 
recommendations were based on concern for accelerated calcification of bioprosthetic valves. 333 
However, several studies subsequently have shown that there was no difference in survival 334 
between patients who received mechanical versus biological prostheses (4,9,12-15).  The most 335 
notable study done by Herzog et al. retrospectively identified 5858 dialysis patients who 336 
underwent heart valve replacement surgery from the US Renal Data System database.  It showed 337 
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that survival with tissue prosthetic valves at 5 years was 13.8% vs 14.9% in patients who 338 
received mechanical valves (5). The guidelines were subsequently updated in 2006 and 2014, 339 
and they no longer have specific recommendations for valve selection in this patient population. 340 
It is recommended to individualize prosthesis selection.  However, choice of valve type remains 341 
difficult as there is limited data defining long-term survival in this population (3,12). 342 
Our findings of very poor long-term survival (13% overall at 10 years) mirrors the US 343 
renal data system estimation of survival as well as other studies (16, 17). After adjusting for age, 344 
NYHA class, and diabetes there was no difference in survival between those who had biological 345 
valves, or those who had mechanical valves placed in this current stud. Furthermore, propensity 346 
score matching corroborated our multivariable analysis.    347 
To delineate who might live long enough to warrant a mechanical valve, a Cox-348 
Regression analysis was performed to estimate survival based on 5 different ages (30, 40, 50, 60, 349 
or 70 years old), and the presence of diabetes and/or heart failure. Only patients aged 30 or 40 350 
years old in NYHA class I-II failure without diabetes had a >50% estimated 5-year survival 351 
(Figure 4, Table 4).  In our study, this represented only 24 patients, or 7% of the total group of 352 
423. In our model, a physician can evaluate a patient based on age, and presence of diabetes or 353 
heart failure and gain insight regarding survival following valve replacement.  This model may 354 
help guide valve selection in this complicated group of patients. Larger prospective studies are 355 
needed to corroborate our findings.  356 
In our study 15% of patients with biological valves were readmitted versus 28% of 357 
patients with mechanical valves within 30 days of discharge.  Of those who had a known reason 358 
for readmission, 10/70 (14%) in the mechanical valve group were readmitted for bleeding 359 
complications versus 6/70 (8.5%) in the biological valve group. The majority of bleeding 360 
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complications occurred within the first few months of initiation of anticoagulation.  Because 361 
anticoagulation carries an increased risk of morbidity and inconveniences these patients, 362 
mechanical valves should be reserved for only those with an estimated long term survival that is 363 
longer than the time a biological valve might deteriorate.  This study suggests that only very 364 
young people (e.g.30-40 years old) without diabetes or NYHA III or IV symptoms have a high 365 
enough estimated survival to warrant consideration of a mechanical valve and anticoagulation.  366 
The limitations of this study include that it was retrospective in nature and thus subject to 367 
the threats inherent to this design.  Furthermore, as no standardized protocols were used for the 368 
selection of valve type, surgeon bias likely influenced the data. We had limited 369 
echocardiographic data to confirm the longevity of valves.  Due to limitation of databases and 370 
data accrual from a multi-institutional study, follow up of patients was not 100% complete, 371 
which limits the accuracy of results.  However, estimated survival rates were highly statistically 372 
significant, which indicates sufficient numbers were available for estimation of long-term 373 
mortality.   A larger prospective randomized study would be needed to corroborate our results.   374 
In conclusion, patients who require dialysis and undergo valve replacement surgery have 375 
poor long-term survival. Valve type must ultimately be tailored to each patient.  Since most 376 
patients have very poor short term (<5 year) survival, biological valves should be strongly 377 
considered. In our model, only young patients (age 30 or 40), without diabetes or NYHA III or 378 
IV symptoms had an estimated 5-year survival >50%; Therefore, only in this small segment of 379 
the overall population may it be justifiable to place a mechanical valve.  380 
 381 
 382 
 383 
 384 
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Table 1: Preoperative characteristics of hemodialysis-dependent patients who underwent valve 385 
replacement with biologic or mechanical valves 386 
Preoperative Variable Biologic(n=341) Mechanical (n=82) p value 
   Age 60.1 ± 13.5 50.9 ±12.8 <0.001 
   Gender (Female) 123 (36) 30 (37) 0.898 
   BMI 29.2 ±7.8 29.9 ±8.2 0.581 
   Race (white) 222 (65) 50 (62) 0.605 
   Euro Score II 9.43±7.86 6.79±6.71 0.002 
   NYHA Class III or IV 234 (68) 54 (66) 0.872 
   Ejection Fraction 50.8 ±14.9 53.5 ±14.9 0.170 
   Smoker 141 (42) 38 (47) 0.885 
   HTN 304 (89) 73 (90) 0.845 
   Cerebrovascular disease 93 (27%) 15 (18%) 0.062 
   Dyslipidemia 201 (59%) 40 (48%) 0.112 
   Diabetes 159 (46) 32 (40) 0.267 
   PVD 103 (30) 16 (20) 0.074 
   Chronic Lung Disease 107 (31) 19 (23) 0.070 
   Previous Sternotomy 81 (23) 14 (17) 0.239 
   Previous valve operation 54 (15) 11 (13) 0.731 
   Endocarditis 121 (35) 24 (30) 0.364 
Intraoperative Variable    
    AVR  
    MVR  
    Two or more valves 
     AVR + MVR  
     AVR +MVR + TVR 
     AVR + TVR 
     MVR + TVR                           
211 
89 
41 
39 
1 
1 
0 
42 
28 
12 
10 
0 
1 
1  
N/A 
   Cross clamp time (min) 118.8 ±57 127.0 ±64 0.301 
   CPB time (min) 169.4±76 185.38±90 0.148 
   Tricuspid valve procedure 28 (8%) 8 (10%) 0.36 
   Concomitant CABG 96 (28) 15 (18.2) 0.092 
BMI, body mass index; NYHA, New York Heart Association Heart Failure Class. HTN, 387 
hypertension. PVD, peripheral vascular disease.  AVR, aortic valve replacement.  MVR, mitral valve 388 
replacement. TVR, tricuspid valve repair or replacement.  CPB, cardiopulmonary bypass.  CABG, 389 
coronary artery bypass 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
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Table 2: Postoperative outcomes of dialysis dependent patients who underwent valve replacement 401 
with biological or mechanical valves.  402 
Variable Biologic (n=341) Mechanical (n=82) p value 
Ventilator Hours 33[10,118] 19[10,117] 0.081 
Reoperation for bleeding 16 (5) 5 (6) 0.572 
Sepsis 42 (12) 5 (6) 0.167 
Stroke 14 (4) 4 (5) 0.759 
Atrial fibrillation 109 (32) 23 (28) 0.595 
Length of Stay 13 [5, 21] 13 [8,22] 0.632 
30 day Mortality 47 (14) 8 (10) 0.462 
30 day readmission 50 (15) 23 (28) 0.005 
Readmission for bleeding 6/70(8.5) 10/70(14) 0.084 
 403 
 404 
Table 3: Univariable and multivariable predictors of mortality following valve replacement in 405 
patients with end stage renal disease who required hemodialysis. 406 
HTN, Hypertension. NYHA, New York Heart Association. CVD, Cerebrovascular disease. PVD, 407 
Peripheral vascular disease 408 
 409 
 410 
 411 
 Univariable Analysis Multivariable Analysis 
Variable Hazard Ratio 95% CI p-value Hazard Ratio 95% CI p value 
Age 1.03 1.02-1.04 <0.001 1.09 1.011-1.11 <0.001 
Gender 1.02 0.96-1.53 0.13    
Race  1.02 0.91-1.52 0.24    
BMI 1.00 0.99-1.03 0.42    
EuroScore II 1.01 1.00-1.05 0.14    
NYHA Class III or IV 1.39 1.03-1.89 0.033 1.36 1.01-1.82 0.048 
Ejection Fraction 0.98 0.97-0.99 0.12    
Smoker 1.10 0.97-1.61 0.17    
HTN 0.91 0.62-1.33 0.64    
CVD 1.03 0.85-1.40 0.50    
Dyslipidemia 1.00 0.78-1.30 0.97    
PVD 0.76 0.61-0.99 0.14    
Chronic Lung Disease 0.91 0.72-1.16 0.91    
Previous Sternotomy 0.79 0.61-1.04 0.11    
Previous Valve  0.86 0.62-1.20 0.86    
Endocarditis 1.21 0.89-1.52 0.30    
Diabetes 1.41 1.25-1.63 0.001 1.54 1.21-2.01 0.001 
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Figure 1: Unadjusted Kaplan Meier analysis for dialysis-dependent patients undergoing valve 412 
replacement with mechanical vs biological valves. 413 
 414 
Figure 2: Overall survival of dialysis-dependent patients undergoing valve replacement surgery 415 
with biological and/or mechanical valves.  Four hundred twenty three patients were included in 416 
the analysis.  417 
 418 
Figure 3: Cox regression analysis for patients undergoing valve replacement.  Estimation of 5 419 
year survival was generated using a cox regression analysis. Variables included in this model 420 
were age, NYHA III or IV symptoms, and presence of diabetes which were all significant 421 
predictors of mortality.  422 
 423 
Figure 4:  Patient plots showing estimated survival for a 30 year old dialysis-dependent patient 424 
without diabetes and NYHA III or IV heart failure symptoms and a 70 year old dialysis-425 
dependent patient with diabetes and NYHA III or IV symptoms following valve replacement 426 
using a cox regression analysis. (p=<0.001) DM-Diabetes mellitus, NYHA-New York Heart 427 
Association. 428 
 429 
Supplementary Figure 1:  Variables included in the propensity analysis and their before and after 430 
matching standardized differences. PVD-Peripheral vascular disease, CVD- cerebrovascular 431 
disease, NYHA-New York Heart Association, CAD- Coronary artery disease. 432 
 433 
Supplementary Figure 2: Standard differences pre-propensity matching. 434 
 435 
Supplementary Figure 3: Standard differences post-propensity matching. 436 
 437 
Supplementary Figure 4: Survival analysis of propensity-matched groups using Kaplan Meier 438 
method.  439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
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Table 4: Estimated 5 year survival based on 5 ages (p<0.001, HR 1.09: 95% CI [1.01-1.11]), 447 
diabetes (p<0.001, HR 1.54: 95% CI [1.21-2.01]), and/or NYHA heart failure symptoms 448 
(p=0.048, HR 1.36: 95% CI [1.01-1.82]). 449 
 Age Group             No Diabetes            + Diabetes 
 
 NYHA I-II   NYHA III-IV NYHA I-II   NYHA III-IV 
30 years 61% 50% 46% 35% 
40 years 54% 43% 38% 27% 
50 years 46% 34% 30% 19% 
60 years 35% 27% 22% 13% 
70 years 31% 19% 16% 8% 
NYHA, New York Heart Association Heart Failure Class. HR, Hazard Ratio 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
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 474 
 475 
 476 
 477 
 478 
 479 
 480 
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